Adaptation of a European categorization system for driving-impairing medicines in Iran

References

• Álvarez FJ. 2016. Parkinson’s disease, anti Parkinson medicines, and driving. Expert Rev Neurother. 16(9):1023–1032. doi:10.1080/14737175.2016.1218278.
   PubMed Web of Science ®Google Scholar
• Álvarez González FJ, Gómez Talegón T, Fl MI. 2011. Establishment of framework for classification/categorisation and labelling of medicinal drugs and driving (DRUID Deliverable 4.3). [accessed 2011 Oct 14]. https://www.bast.de/Druid/EN/deliverales-list/deliverables-list-node.html.
   Google Scholar
• Assari S, Moghani Lankarani M, Dejman M, Farnia M, Alasvand R, Sehat M, Roshanpazooh M, Tavakoli M, Jafari F, Ahmadi K. 2014. Drug use among Iranian drivers involved in fatal car accidents. Front Psychiatry. 5:69. doi:10.3389/fpsyt.2014.00069.
   PubMed Web of Science ®Google Scholar
• Brunnauer A, Buschert V, Fric M, Distler G, Sander K, Segmiller F, Zwanzger P, Laux G. 2015. Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry. 48(2):65–71. doi:10.1055/s-0034-1398509.
   PubMed Web of Science ®Google Scholar
• Buckley SE, Robinson K, Stapleton T. 2017. Driving and depression: health professional’s perspectives in Ireland. J Transp Health. 7:235–246. doi:10.1016/j.jth.2017.09.003.
   Web of Science ®Google Scholar
• De Gier JJ, Ravera S, Monteiro SP, Fj A. 2011. Establishment of criteria for a European categorisation system for medicines and driving (DRUID Deliverable 4.2.1). [accessed 2011 Oct 05]. https://www.bast.de/Druid/EN/deliverales-list/deliverables-list-node.html.
   Google Scholar
• Del Río MC, Álvarez FJ. 2003. Medication and fitness to drive. Pharmacoepidemiol Drug Saf. 12(5):389–394. doi:10.1002/pds.806.
   PubMed Web of Science ®Google Scholar
• Emich B, Van Dijk L, Monteiro SP, De Gier JJ. 2014. A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines. Int J Clin Pharm. 36(6):1152–1159. doi:10.1007/s11096-014-0010-2.
   PubMed Web of Science ®Google Scholar
• Fierro I, Gómez-Talegón T, Alvarez FJ. 2013. The Spanish pictogram on medicines and driving: the population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev. 50:1056–1061. doi:10.1016/j.aap.2012.08.009.
   PubMed Web of Science ®Google Scholar
• Fukuda Y, Ando S, Saito M. 2020. Effect of a Japanese drug alert pictogram on medication-taking/driving behavior. Traffic Inj Prev. 21(1):18–23. doi:10.1080/15389588.2019.1680838.
   PubMed Web of Science ®Google Scholar
• Ghadirzadeh M, Forouzesh M, Barzegar A, Mirtorabi SD, Hedayatshodeh M, Mohajerpour AM. 2018. Patterns of drunk and drugged driving in fatally injured drivers in Tehran. Iran. IJMTFM. 8(4):137–144. doi:10.22037/ijmtfm.v8i4(Autumn).22963.
   Google Scholar
• Harzand-Jadidi S, Pourasghar F, Sadeghi-bazargani H, and Farahbakhsh M. 2023. Categorization and labeling systems concerning driving-impairing medicines: a scoping review. Traffic Inj Prev. 24(4):287–292. doi:10.1080/15389588.2022.2150393
   PubMedGoogle Scholar
• Huizinga CR, Zuiker RG, de Kam ML, Ziagkos D, Kuipers J, Mejia Y, van Gerven JM, Cohen AF. 2019. Evaluation of simulated driving in comparison to laboratory-based tests to assess the pharmacodynamics of alprazolam and alcohol. J Psychopharmacol. 33(7):791–800. doi:10.1177/0269881119836198.
   PubMed Web of Science ®Google Scholar
• Ivers T, White ND. 2016. Potentially driver-impairing medications: risks and strategies for injury prevention. Am J Lifestyle Med. 10(1):17–20. doi:10.1177/1559827615609050.
   PubMedGoogle Scholar
• Touliou K, Monteiro S, Ravera S. 2011. Report on the implementation, evaluation and new technologies of practice guidelines and information materials (Deliverable D.7.4.2). [accessed 2011 Aug 1]. https://www.bast.de/Druid/EN/deliverales-list/deliverables-list-node.html.
   Google Scholar
• Legrand S-A, Boets S, Meesmann U, Verstraete AG. 2012. Medicines and driving: evaluation of training and software support for patient counselling by pharmacists. Int J Clin Pharm. 34(4):633–643. doi:10.1007/s11096-012-9658-7.
   PubMed Web of Science ®Google Scholar
• Lloyd S. 2012. Assessing fitness to drive for commercial and private vehicle drivers (medical standards for licensing and clinical management guidelines—a resource for health professionals in Australia). Oxford: Oxford University Press.
   Google Scholar
• Lotfi S, Yazdanirad S, Pourabdiyan S, Hassanzadeh A, Lotfi A. 2017. Driving behavior among different groups of Iranian drivers based on driver coping styles. Int J Prev Med. 8(1):52. doi:10.4103/ijpvm.IJPVM_313_16.
   PubMedGoogle Scholar
• Monteiro SP, Huiskes R, Dijk LV, Van Weert JC, De Gier JJ. 2013. How effective are pictograms in communicating risk about driving-impairing medicines? Traffic Inj Prev. 14(3):299–308. doi:10.1080/15389588.2012.710766.
   PubMed Web of Science ®Google Scholar
• Niroomand N, Bayati M, Seif M, Delavari S, Delavari S. 2020. Self-medication pattern and prevalence among Iranian medical sciences students. Curr Drug Saf. 15(1):45–52. doi:10.2174/1574886314666191022095058.
   PubMed Web of Science ®Google Scholar
• Pil K, R E, Van den Neste T, Goessaert A, V J, V A. 2008. Review of existing classification efforts (Deliverable 4.1.1). [accessed 2008 May 15]. https://www.bast.de/Druid/EN/deliverales-list/deliverables-list-node.html.
   Google Scholar
• Ravera S, Monteiro SP, de Gier JJ, Van der Linden T, Gómez‐Talegón T, Álvarez FJ, Partners DPW. 2012. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 74(6):920–931. doi:10.1111/j.1365-2125.2012.04279.x.
   PubMed Web of Science ®Google Scholar
• Redelmeier DA, Tien HC. 2014. Medical interventions to reduce motor vehicle collisions. CMAJ. 186(2):118–124. doi:10.1503/cmaj.122001.
   PubMed Web of Science ®Google Scholar
• Redelmeier DA, Yarnell CJ, Thiruchelvam D, Tibshirani RJ. 2012. Physicians’ warnings for unfit drivers and the risk of trauma from road crashes. N Engl J Med. 367(13):1228–1236. doi:10.1056/NEJMsa1114310.
   PubMed Web of Science ®Google Scholar
• Sadeghi-Bazargani H, Ayubi E, Azami-Aghdash S, Abedi L, Zemestani A, Amanati L, Moosazadeh M, Syedi N, and Safiri S. 2016. Epidemiological patterns of road traffic crashes during the last two decades in Iran: a review of the literature from 1996 to 2014. Arch Trauma Res. 5(3). doi:10.5812/atr.32985
   PubMedGoogle Scholar
• Schulze H, Schumacher M, Urmeew R, Alvarez J, Bernhoft IM, de Gier JJ, Hagenzieker M, Houwing S, Knoche A, Pilgerstorfer M. 2012. Driving under the influence of drugs, alcohol and medicines in Europe—findings from the DRUID project.
   Google Scholar
• Shams M, Rahimi-Movaghar V. 2009. Risky driving behaviors in Tehran, Iran. Traffic Inj Prev. 10(1):91–94. doi:10.1080/15389580802492280.
   PubMed Web of Science ®Google Scholar
• Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. 2013. Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels. Traffic Inj Prev. 14(6):557–564. doi:10.1080/15389588.2012.729278.
   PubMed Web of Science ®Google Scholar
• Strand MC, Mørland J, Slørdal L, Riedel B, Innerdal C, Aamo T, Mathisrud G, Vindenes V. 2017. Conversion factors for assessment of driving impairment after exposure to multiple benzodiazepines/z-hypnotics or opioids. Forensic Sci Int. 281:29–36. doi:10.1016/j.forsciint.2017.10.022.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Matsumoto K, Kuroda Y, Oohara H, Kizu J. 2016. Pharmacy pharmacist’s response to prescription of medicines that affect driving. J Jpn Counc Traffic Sci. 15(3):29–37. doi:10.24597/jcts.15.3_29.
   Google Scholar
• Veldhuijzen DS, van Wijck AJ, Verster JC, Kalkman CJ, Kenemans JL, Olivier B, Volkerts E. 2006. The impact of chronic pain patients’ psychotropic drug knowledge and warning labels on the decision whether to drive a car or not. Traffic Inj Prev. 7(4):360–364. doi:10.1080/15389580600943005.
   PubMedGoogle Scholar
• Verster JC, Mets MA. 2009. Psychoactive medication and traffic safety. Int J Environ Res Public Health. 6(3):1041–1054. doi:10.3390/ijerph6031041.
   PubMed Web of Science ®Google Scholar
• Vindenes V, Boix F, Koksæter P, Strand MC, Bachs L, Mørland J, Gjerde H. 2014. Drugged driving arrests in Norway before and after the implementation of per se law. Forensic Sci Int. 245:171–177. doi:10.1016/j.forsciint.2014.10.038.
   PubMed Web of Science ®Google Scholar
• Wolschrijn H, Gier JJ, Smet PAGM. 1991. Drugs & driving: new categorization system for drugs affecting psychomotor performance: institute for drugs. Tech Report. The Netherlands: University of Limburg. Safety and Behavior.
   Google Scholar
• World Health Organization. 2022. Anatomical therapeutic chemical (ATC) Classification. World health organization (WHO), [accessed 2022]. https://www.who.int/tools/atc-ddd-toolkit/atc-classification.
   Google Scholar